EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalisation for heart-failure and cardiovascular death. Find out more here.